Learn About Usher Syndrome

What is the definition of Usher Syndrome?

Usher syndrome is a condition characterized by partial or total hearing loss and vision loss that worsens over time. The hearing loss is classified as sensorineural, which means that it is caused by abnormalities of the inner ear. The loss of vision is caused by an eye disease called retinitis pigmentosa (RP), which affects the layer of light-sensitive tissue at the back of the eye (the retina). Vision loss occurs as the light-sensing cells of the retina gradually break down. Loss of night vision begins first, followed by blind spots that develop in the side (peripheral) vision. Over time, these blind spots enlarge and merge to produce tunnel vision. In some cases, vision is further impaired by clouding of the lens of the eye (cataracts). However, many people with retinitis pigmentosa retain some central vision throughout their lives.

What are the causes of Usher Syndrome?

Usher syndrome can be caused by mutations in several different genes. Mutations in at least six genes can cause Usher syndrome type I. The most common of these are MYO7A gene mutations, followed by mutations in the CDH23 gene. Usher syndrome type II can result from mutations in three genes; USH2A gene mutations account for most cases of type II. Usher syndrome type III is most often caused by mutations in the CLRN1 gene.

How prevalent is Usher Syndrome?

Usher syndrome affects around 4 to 17 in 100,000 people. Types I and II are the most common forms of Usher syndrome in most countries. Certain genetic mutations resulting in type 1 Usher syndrome are more common among people of Ashkenazi (eastern and central European) Jewish or French Acadian heritage than in the general population.

Is Usher Syndrome an inherited disorder?

All of the types of Usher syndrome are inherited in an autosomal recessive pattern, which means both copies of a gene in each cell have a mutation. The parents of an individual with Usher syndrome each carry one copy of the mutated gene, but they do not have any signs and symptoms of the condition.

Who are the top Usher Syndrome Local Doctors?
Elite in Usher Syndrome
Elite in Usher Syndrome

University Of North Carolina At Chapel Hill

2226 Nelson Hwy, Suite 200, 
Chapel Hill, NC 
Languages Spoken:
English
Accepting New Patients

Alessandro Iannaccone is an Ophthalmologist in Chapel Hill, North Carolina. Dr. Iannaccone is rated as an Elite provider by MediFind in the treatment of Usher Syndrome. His top areas of expertise are Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, X-Linked Retinitis Pigmentosa (XLRP), and Usher Syndrome Type 2A. Dr. Iannaccone is currently accepting new patients.

Elite in Usher Syndrome
Ophthalmology
Elite in Usher Syndrome
Ophthalmology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
Languages Spoken:
English

Jacque Duncan is an Ophthalmologist in San Francisco, California. Dr. Duncan is rated as an Elite provider by MediFind in the treatment of Usher Syndrome. Her top areas of expertise are Usher Syndrome Type 2A, Usher Syndrome, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, and Vitrectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Usher Syndrome
Elite in Usher Syndrome
Paris, FR 

Christine Petit practices in Paris, France. Ms. Petit is rated as an Elite expert by MediFind in the treatment of Usher Syndrome. Her top areas of expertise are Usher Syndrome, Hearing Loss, Retinitis Pigmentosa, and Retinopathy Pigmentary Mental Retardation.

What are the latest Usher Syndrome Clinical Trials?
A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Summary: The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

Summary: Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT...

Who are the sources who wrote this article ?

Published Date: May 17, 2021
Published By: National Institutes of Health